Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Alloantibody and autoantibody monitoring predicts islet transplantation outcome in human type 1 diabetes.

Authors
  • Piemonti, Lorenzo1
  • Everly, Matthew J
  • Maffi, Paola
  • Scavini, Marina
  • Poli, Francesca
  • Nano, Rita
  • Cardillo, Massimo
  • Melzi, Raffaella
  • Mercalli, Alessia
  • Sordi, Valeria
  • Lampasona, Vito
  • Espadas de Arias, Alejandro
  • Scalamogna, Mario
  • Bosi, Emanuele
  • Bonifacio, Ezio
  • Secchi, Antonio
  • Terasaki, Paul I
  • 1 Diabetes Research Institute, San Raffaele Hospital Scientific Institute, Milan, Italy. [email protected] , (Italy)
Type
Published Article
Journal
Diabetes
Publication Date
May 01, 2013
Volume
62
Issue
5
Pages
1656–1664
Identifiers
DOI: 10.2337/db12-1258
PMID: 23274902
Source
Medline
License
Unknown

Abstract

Long-term clinical outcome of islet transplantation is hampered by the rejection and recurrence of autoimmunity. Accurate monitoring may allow for early detection and treatment of these potentially compromising immune events. Islet transplant outcome was analyzed in 59 consecutive pancreatic islet recipients in whom baseline and de novo posttransplant autoantibodies (GAD antibody, insulinoma-associated protein 2 antigen, zinc transporter type 8 antigen) and donor-specific alloantibodies (DSA) were quantified. Thirty-nine recipients (66%) showed DSA or autoantibody increases (de novo expression or titer increase) after islet transplantation. Recipients who had a posttransplant antibody increase showed similar initial performance but significantly lower graft survival than patients without an increase (islet autoantibodies P < 0.001, DSA P < 0.001). Posttransplant DSA or autoantibody increases were associated with HLA-DR mismatches (P = 0.008), induction with antithymocyte globulin (P = 0.0001), and pretransplant panel reactive alloantibody >15% in either class I or class II (P = 0.024) as independent risk factors and with rapamycin as protective (P = 0.006) against antibody increases. DSA or autoantibody increases after islet transplantation are important prognostic markers, and their identification could potentially lead to improved islet cell transplant outcomes.

Report this publication

Statistics

Seen <100 times